WASHINGTON - U.S. regulators on Thursday formally approved an Alzheimer's drug developed by Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. that has become the world's first medicine shown to slow the onset of the degenerative brain disease.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
